The science behind the products developed by Immunethep is linked with the discovery of a virulence immunosuppressive mechanism shared by different bacteria.
Research showed that different bacteria actively excrete a protein, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). In extracellular environment, the bacterial GAPDH engages toll-like receptor (TLR)-2 on the surface of B lymphocytes which leads to a very fast production of Interleukin (IL)-10 in the host, which in turn causes the systemic immune-suppression.
A New Approach
The solutions developed by Immunethep have been designed to block the bacterial GAPDH with specific antibodies, while not reacting with human GAPDH. By doing so, the host immune system is fully capable of dealing with the infection and eliminating the invasive bacteria.
This blockage of bacterial GAPDH can be performed preventively, with a vaccine, or therapeutically, using monoclonal antibodies.
IMMUNETHEP developed the Platform of Immunomodulatory Therapies for Infectious Diseases.
With the PIT-ID platform, Immunethep addresses AMR from three different perspectives: Pathogens, Hosts, and Immunotherapies.
The platform is backed by the company’s proprietary technology to create a set of products that can serve different targets, approaches, and markets.